(HALT) Embrace Hydrogel Embolic System (HES) Study of Embolization in Peripheral Arterial Bleeds

NCT05364502 | Active Not Recruiting DMC FDA Device

• 1 other identifier: INY-P-21-002
• Study Type: interventional
• Target: 130
• Locations: 1 country
• Sites: 22

Brief Summary

To evaluate the safety and effectiveness of Embrace Hydrogel Embolic System for the transcatheter embolization of peripheral arterial bleeds.

Conditions

Arterial Bleeding in Solid Organs and Peripheral Arteries

Outcome Measures

Primary Outcomes (3)

• Primary safety endpoint

  Freedom from major adverse events (MAE)

  Through 30 days post-index procedure

• Clinical Success

  Defined as the absence of bleeding from the target lesion after embolization with Embrace HES without the need for subsequent embolic devices in the index procedure, emergency surgery, re-embolization or other target vessel re-interventions due to rebleeding.

  Within 30 days of the index procedure

• Technical Success

  Defined as occlusion of the target vessel or exclusion of the area of arterial damage and/or the cessation of extravasation on angiography after embolization with Embrace HES.

  Immediately following index procedure

Interventions

Embrace HES including Instylla™ Delivery Kit and Instylla™ Microcatheter DEVICE

The Embrace Hydrogel Embolic System (HES) is indicated for embolization of peripheral arterial bleeds in vessels ≤6mm

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female patients age ≥ 18 years old
• Subjects who are candidates for transarterial catheter embolization with arterial bleeding documented on a suitable radiologic imaging and/or endoscopic visualization study taken during the index hospitalization that allows for the source of the arterial injury/bleeding to be localized. Includes (but not limited to) the following:
• Non-variceal Upper Gastrointestinal (UGI) bleeds refractory to endoscopic treatment
• End organ/visceral bleeds (kidney, liver and spleen including tumor bleeds)
• Spontaneous hematoma (e.g., rectus sheath and psoas muscle hematomas)
• Other peripheral arterial bleeds (e.g., pelvic hemorrhage) if not associated with risk of ischemia distal to the lesion or embolization of non-expendable arteries.
• Subjects with at least one target vessel ≤6mm and Embrace HES can be delivered to the target vessel(s).
• Subject is willing to comply with follow-up evaluation schedule.
• No prior embolization in the target territory prior to study entry
• The subject or a legally authorized representative has provided informed consent approved by the appropriate local IRB/EC.

You may not qualify if:

• Life expectancy ≤ 30 days
• In the Investigator's opinion, due to injury severity the subject is not likely to benefit from angioembolization (e.g., in the presence of significant polytrauma, multiple organ failure or shattered organs).
• Any contraindication to arteriography or the embolization protocol utilized at treating institution.
• Pregnant or breast-feeding (women of child-bearing potential must undergo a pregnancy test performed in accordance with local institutional requirements and agree to use contraception for at least six months).
• Hemorrhagic shock (Class IV-see Appendix 1) at time of treatment
• Target vascular territory supplied by the pulmonary artery, coronary artery, or cerebral or cerebellar artery (requiring embolization of these arteries) or the artery to be embolized has connections to these arteries via a collateral pathway.
• Embolization for treatment of spinal arteries, lower GI bleeds, arteriovenous malformations, embolization of arteriovenous shunts, endoleak management, neurovascular bleeds, penetrating trauma of extremities.
• Forrest Classification Type III UGI bleeds (see Appendix 2)
• In the investigator's opinion, patient will require embolization of 4 or more discrete vascular territories/arterial injuries (requires that microcatheter be repositioned to discrete area) based on diagnostic angiography or another suitable imaging study.
• Known or suspected angio-anatomical conditions that in the Investigator's opinion, would prevent the delivery catheter to gain access to the selected position for safe and intended embolization.
• Known allergies (based on history) to PEG, ferrous compounds, tert Butyl Hydroperoxide, contrast media or procedural sedatives/anesthetics that is not amenable to pre-medication
• Presence of medically relevant localized or systemic infection
• The patient has other concurrent conditions or known history that in the opinion of the Investigator would be unlikely to receive clinical benefit from the study procedure or participation in the study may compromise patient safety or study objectives (including but not limited to ongoing acute infection, life-threatening concomitant trauma or conditions).
• Presence of Uncorrectable Coagulopathy: Defined as thrombocytopenia with platelet counts \< 40,000/mm3 and/or INR \> 2.0.
• If known, enrollment in a concurrent study in which the study treatment may confound the evaluation of the study device.

Sponsors & Collaborators

• Instylla, Inc.: lead

Study Sites (22)

Banner Health

Phoenix, Arizona, 85006, United States

Location

Memorial Health Services

Long Beach, California, 92708, United States

Location

Stanford University

Stanford, California, 94305, United States

Location

UCLA Harbor Lindquist Institute

Torrance, California, 90502, United States

Location

Nuvance Health

Danbury, Connecticut, 06810, United States

Location

Yale University

New Haven, Connecticut, 06520, United States

Location

Medstar Georgetown University

Washington D.C., District of Columbia, 20007, United States

Location

University of Miami

Miami, Florida, 33136, United States

Location

Northwestern

Evanston, Illinois, 60611, United States

Location

Indiana University

Indianapolis, Indiana, 46902, United States

Location

University of Maryland

Baltimore, Maryland, 21201, United States

Location

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location

Boston Medical Center

Boston, Massachusetts, 02118, United States

Location

Mount Sinai Hospital

New York, New York, 10029, United States

Location

Columbia University Milstein

New York, New York, 10032, United States

Location

UNC School of Medicine

Chapel Hill, North Carolina, 27599, United States

Location

University of Cincinnati

Cincinnati, Ohio, 45267, United States

Location

University of Oklahoma

Oklahoma City, Oklahoma, 73104, United States

Location

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

University of Pittsburgh

Pittsburgh, Pennsylvania, 15213, United States

Location

Prisma Health

Greenville, South Carolina, 29605, United States

Location

Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States

Location

Study Officials

• Suvranu Ganguli

  Boston Medical Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 3, 2022
• First Posted: May 6, 2022
• Study Start: December 12, 2022
• Primary Completion: January 1, 2026
• Study Completion: March 1, 2026
• Last Updated: November 13, 2025

Record last verified: 2025-07

Locations

US (22)